HAVCR2 and myelodysplastic syndrome: Possible candidates for this therapeutic approach in MDS and sAML are miR-22, miR-33, miR-134, and miR-181 [176,177,178,179] as well as miRNAs targeting TIM-3 and CD47, known to be frequently overexpressed in MDS and/or sAML.